Earnings call briefThird-quarter 2026
10x Genomics raises 2026 revenue outlook to $625 million to $635 million
10x Genomics said it now expects about 50 Atera instruments shipped by year-end, up from about 40.
GetSignal 10x Genomics TXG
On its third-quarter call, 10x Genomics said it now expects 2026 revenue of $625 million to $635 million, up from $610 million to $630 million. The company said the exclusion of nonrecurring patent litigation settlement revenue in both 2026 and 2025 applies to growth of 4% to 6% over full-year 2025.
Taich said fourth-quarter gross margin will be in the low to mid-60s as Atera shipments ramp.
Quotes from the call
“We are raising our full year outlook and now expect 2026 revenue to be in the range of $625 million to $635 million, up from $610 million to $630 million.”
Key facts from the call
- 2026 revenue outlook
- $625 million to $635 million, up from $610 million to $630 million
- Expected 2026 Atera instrument shipments
- About 50, up from about 40
- Fourth-quarter gross margin outlook
- Low to mid-60s
Source: 10x Genomics' third-quarter 2026 earnings call, November 5, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
